Comparative efficacy and safety of carbapenems vs noncarbapenem antibiotics in AmpC-producing Enterobacterales infections: A systematic review and meta-analysis
Abstract
OBJECTIVES: This systematic review and meta-analysis evaluated the clinical efficacy and safety of carbapenems vs noncarbapenem antibiotics in adult hospitalized patients with AmpC-producing Enterobacterales infections across various infection sites. METHODS: A comprehensive search of PubMed, Embase, and Cochrane Library databases was conducted for observational studies and randomized controlled trials comparing carbapenems with alternative agents. Primary outcomes included 30-day all-cause mortality, microbiological failure, infection recurrence, and adverse drug reactions (ADRs). RESULTS: Seventeen studies met the inclusion criteria. There was no significant difference in 30-day mortality (odds ratio [OR] = 1.29; 95% CI: 0.91-1.82; P = 0.16) or infection recurrence (OR = 0.98; 95% CI: 0.32-2.97; P = 0.97) between carbapenems and noncarbapenems. Microbiological failure rates were also comparable. However, carbapenems were associated with a higher incidence of ADRs (OR = 4.32; 95% CI: 1.73-10.79; P = 0.03). Clinical success trended in favor of noncarbapenem agents, though the difference did not reach statistical significance (OR = 0.56, 95% CI: 0.29-1.08; P = 0.08). CONCLUSION: While carbapenems remain effective for AmpC-producing infections, noncarbapenem alternatives offer comparable outcomes with fewer adverse events. These findings support IDSA guidance recommending agents such as cefepime when the minimum inhibitory concentration is ≤2 µg/ml and highlight the need for…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.